| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9364439 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 10 months ago) | |
| US6926907 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(1 year, 1 month ago) | |
| US8206741 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(1 year, 1 month ago) | |
| US9987231 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Jan, 2033
(8 years from now) | |
| US9539214 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Mar, 2033
(8 years from now) | |
Yosprala is owned by Genus Lifesciences.
Yosprala contains Aspirin; Omeprazole.
Yosprala has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Yosprala are:
- US9364439
- US6926907
- US8206741
Yosprala was authorised for market use on 14 September, 2016.
Yosprala is available in tablet, delayed release;oral dosage forms.
Yosprala can be used as treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers, for secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers.
The generics of Yosprala are possible to be released after 13 March, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 14, 2019 |
Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient
Market Authorisation Date: 14 September, 2016
Treatment: Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers; For secondary prevention of cardi...
Dosage: TABLET, DELAYED RELEASE;ORAL
YOSPRALA family patents
